Pennsylvania's life sciences industry sent a message Tuesday to state legislators: Send more money to growing companies.
"We need early-stage capital so we can retain these companies in Pennsylvania," said Gary Glausser, partner at Birchmere Ventures, North Side. Much of the venture capital firm's $160 million is invested in biotechnology and medical companies.
"Venture capital firms want to see more mature companies before they will invest," said Glausser. "So, there's a gap."
Members of the Democratic and Republican policy committees of the state House invited life science and biotechnology officials to a hearing in South Oakland to discuss what the industry most needs.
To read the full, original article click on this link: Sparse funds stunt growth, biotech firms say - Pittsburgh Tribune-Review
Author: This email address is being protected from spambots. You need JavaScript enabled to view it.
